[The results of ovarian cancer therapy in the Hungarian Centers in 2002-2003]
| Autor: | Pulay T, Baki M, György Bodoky, Dank M, Cseh J, Csejtei A, Csömör S, Erfán J, Esik O, Faluhelyi Z, Izsó J, Hernádi Z, Kammerer K, Magyar T, Mayer A, Megyery E, Moskovits K, Pécsi L, Pikó B, Pintér T, Ruzsa A, Szánthó A, Szántó I, Szántó J, Szucs M, Tálos Z, Thurzó L, Kásler M |
|---|---|
| Rok vydání: | 2007 |
| Předmět: |
Adult
Ovarian Neoplasms Hungary Paclitaxel Ovariectomy Carcinoma Brenner Tumor Middle Aged Adenocarcinoma Mucinous Drug Administration Schedule Carboplatin Cystadenocarcinoma Serous Treatment Outcome Chemotherapy Adjuvant Antineoplastic Combined Chemotherapy Protocols Humans Female Carcinoma Endometrioid Aged Retrospective Studies |
| Zdroj: | Europe PubMed Central |
| ISSN: | 0030-6002 |
| Popis: | Authors presented data of treatment results and course of disease in 487 ovarian cancer patients treated by primary surgery and paclitaxel-carboplatin combination chemotherapy between July 1, 2002 and December 31, 2003.Most of our patients (87.8%) belonged to the age-group between 40-70 years. Distribution of their histological diagnosis was as 69.6% serous, 10.7% mucinous, 5.1% endometrial and 4.7% undifferentiated carcinoma. The grade distribution was found as 8.4% grade 1, 40.9% grade 2 and 35.9% grade 3.The primary surgery was evaluated as optimal in 41.7%, suboptimal in 37.3% and exploration was performed in 21.1%. Most patients started chemotherapy 20 days after surgery and 74.2% of them got six courses. During the evaluation period 61 intervallum laparotomies were performed, and resulted on 55.7% optimal debulking. Complete remission was found in 58.9%, and partial remission in 14.7% of patients. This treatment resulted on a complete remission in 40.9% at the follow-up of 12 months. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|